Targeted Macrophages Delivery of rifampicin-loaded Lipid Nanoparticles to Improve Tuberculosis Treatment

Abstract

The NLCs developed can be used as a promising carrier for safer and efficient management of tuberculosis.

Optimization of Rifapentine-Loaded Lipid Nanoparticles Using a Quality-by-Design Strategy

“…Lyophilization was performed based on the methods described by Varshosaz et al [21] and Vieira et al [22]. Briefly, the samples were prepared using aerosil 2% (w/w) (Sigma-Aldrich, MA, USA) as cryoprotectant.…”

Nanomedicines towards targeting intracellular Mtb for the treatment of tuberculosis

“…Literature on using nanomedicines to target TB is predominantly based on the use of polymers or liposomes with first‐line drugs RIF or INH. (Pandey et al, ; Pandey and Khuller, ; Pandey and Khuller, ; Ohashi et al, ; Hirota et al, ; Aboutaleb et al, ; Raj et al, ; Chuan et al, ; Dube et al, ; Vieira et al, ; Hakkimane et al, ) Studies have highlighted the possibilities of encapsulating anti‐TB drugs within biodegradable polymer NPs, thus increasing the concentration of drugs at specific sites (e.g., infected macrophages) through targeting. NPs containing anti‐TB drugs are usually made from biodegradable materials (e.g., alginate or solid lipids), and most TB research focuses on the use of poly‐lactic‐ co ‐glycolic acid (PLGA) synthetic polymers.…”

“…created nanostructured lipid carriers (NLCs) as nanocarriers of RIF for selective delivery. (Vieira et al, ) To increase selectivity to macrophages, the NLCs were coated with mannose(Jain et al, ) to target macrophage sugar receptors, and they were evaluated for cellular uptake and their impact on cell viability. The authors treated bone marrow‐derived macrophages (BMDMs) with mannosylated RIF NLCs, RIF NLCs, and native RIF drug.…”

“…The authors treated bone marrow‐derived macrophages (BMDMs) with mannosylated RIF NLCs, RIF NLCs, and native RIF drug. (Vieira et al, ) They followed cellular uptake using fluorescence microscopy and then quantified using flow cytometry. The mannose‐coated RIF NLCs displayed a 14.5‐fold increase in cellular uptake, which is encouraging but also highlights the power of targeting.…”

“…Finally, the authors report that NLCs containing RIF drug exhibited lower levels of cytotoxicity to BMDMs than did NLCs with no drug and account this to the surface charge of the NPs; however, the inclusion of the mannose coating onto RIF NLCs did reduce cell viability. (Vieira et al, )…”